Anavex Life Sciences to Announce Fiscal Second Quarter 2018 Financial Results on Thursday, May 10, 2018
May 09 2018 - 6:00AM
Conference Call and Webcast To be Held Thursday,
May 10, 2018 at 4:30pm Eastern Time
Anavex Life Sciences Corp., (“Anavex” or the “Company”)
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company
developing differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental diseases, including
Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other
central nervous system (CNS) diseases, today announced that it will
issue financial results for the Second Quarter ended March 31, 2018
and provide an update on its Clinical Programs and corporate
highlights on Thursday, May 10, 2018.
Management will host a conference call on
Thursday, May 10, 2018 at 4:30pm Eastern Time to review financial
results and provide an update on its Clinical Programs. Following
management’s formal remarks, there will be a question and answer
session.
Conference Call / Webcast Information
The conference call will be available through a live webcast at
http://www.wsw.com/webcast/cc/avxl5. To listen to the live call by
phone, interested parties within the U.S. should dial, toll-free, 1
(866) 939-3921 and international callers should dial 1 (678)
302-3550. Please use confirmation number 46931087, followed by the
pound sign (#).
A replay of the call will be available
approximately one hour after the end of the call through June 10,
2018 at www.anavex.com.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq:AVXL) is a
publicly traded biopharmaceutical company dedicated to the
development of differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental diseases including
Alzheimer’s disease, other central nervous system (CNS) diseases,
pain and various types of cancer. Anavex’s lead drug candidate,
ANAVEX®2-73, recently completed a successful Phase 2a clinical
trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available
drug candidate that restores cellular homeostasis by targeting
sigma-1 and muscarinic receptors. Preclinical studies demonstrated
its potential to halt and/or reverse the course of Alzheimer’s
disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic,
neuroprotective and anti-depressant properties in animal models,
indicating its potential to treat additional CNS disorders,
including epilepsy. The Michael J. Fox Foundation for Parkinson’s
Research previously awarded Anavex a research grant to develop
ANAVEX®2-73 for the treatment of Parkinson’s disease. The grant
fully funded a preclinical study, which could justify moving
ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71,
which targets sigma-1 and M1 muscarinic receptors, is a promising
preclinical drug candidate demonstrating disease-modifying activity
against the major hallmarks of Alzheimer’s disease in transgenic
(3xTg-AD) mice, including cognitive deficits, amyloid and tau
pathologies. In preclinical trials, ANAVEX®3-71 has shown
beneficial effects on neuroinflammation and mitochondrial
dysfunction. Further information is available at www.anavex.com.
You can also connect with the company
on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks set forth in the Company’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Anavex Life
Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
hereof.
For Further Information:
Anavex Life Sciences Corp.Research &
Business DevelopmentToll-free: 1-844-689-3939Email:
info@anavex.com
Investors & Media:Meggie
Purcell Solebury Trout Email: mpurcell@soleburytrout.com
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Apr 2023 to Apr 2024